{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:06:44Z","timestamp":1786406804387,"version":"build-2736575974"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been widely used in treating type 2 diabetes mellitus (T2DM) and obesity in adults, but scientific research about the indication in children and adolescents is scarce. The current study aims to explore the prescriptions of GLP-1RAs in children and adolescents in China and to evaluate its rationality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>GLP-1RA prescriptions of children and adolescents were retrospectively obtained from the Hospital Prescription Analysis Cooperative Project. The study extracted information on patient\u2019s demographic characteristics, monotherapy and combination therapy of GLP-1RAs, and trends in GLP-1RA usage from 2016 to 2021. The rationality of GLP-1RA prescriptions was comprehensively assessed based on the indications approved by China National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), and published randomized controlled trials (RCTs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 234 prescriptions from 46 hospitals were included, with a median age of 17 years old. The majority of patients were diagnosed with overweight\/obesity or prediabetes\/diabetes, accounting for 43.59% and 46.15%, respectively. There were 88 patients on GLP-1RA monotherapy. GLP-1RAs plus metformin was the most common combination therapy (38.89%). 12.39% of patients were found a co-administration with orlistat. The share of overweight\/obesity prescriptions increased from 27% in 2016 to 54% in 2021, whereas prediabetes\/diabetes prescriptions declined from 55% to 42%. The prescriptions were divided into appropriate and questionable groups according to the diagnosis, and the potentially questionable prescription was related to age (<jats:italic>p<\/jats:italic> = 0.017), department visited (<jats:italic>p<\/jats:italic> = 0.002), and any hospitalization (<jats:italic>p<\/jats:italic> &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study described the prescribing of GLP-1RAs in children and adolescents. Our findings indicated that the utilization of GLP-1RAs has increased from 2016 to 2021. There was a strong basis for administering GLP-1RAs in overweight\/obesity and prediabetes\/diabetes, whereas the evidence was insufficient in other conditions. It is crucial to demand robust and sustained efforts to enhance the awareness of the safety of utilization of GLP-1RAs in children and adolescents.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1170127","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T04:24:55Z","timestamp":1686630295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study"],"prefix":"10.3389","volume":"14","author":[{"given":"Yilong","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meizhu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiping","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.19538\/j.nk2021080106","article-title":"Guidelines for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)","volume":"41","year":"2021","journal-title":"Chin J Pract Internal Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.12.009","article-title":"Newer GLP-1 receptor agonists and obesity-diabetes","volume":"100","author":"Brown","year":"2018","journal-title":"Peptides"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/nu12082208","article-title":"Effects of lifestyle modification interventions to prevent and manage child and adolescent obesity: a systematic review and meta-analysis","volume":"12","author":"Salam","year":"2020","journal-title":"Nutrients"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00045-0","article-title":"Epidemiology and determinants of obesity in China","volume":"9","author":"Pan","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.651589","article-title":"Glycated hemoglobin (HbA1c) concentrations among children and adolescents with diabetes in middle- and low-income countries, 2010-2019: a retrospective chart review and systematic review of literature","volume":"12","author":"Chen","year":"2021","journal-title":"Front Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.47186","article-title":"The prevalence of obesity among children with type 2 diabetes: a systematic review and meta-analysis","volume":"5","author":"Cioana","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-8587(17)30186-9","article-title":"Type 2 diabetes in adolescents and young adults","volume":"6","author":"Lascar","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jpeds.2021.05.009","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: a meta-analysis","volume":"236","author":"Ryan","year":"2021","journal-title":"J Pediatr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2014.21","article-title":"Prevalence and trends in obesity and severe obesity among children in the united states, 1999-2012","volume":"168","author":"Skinner","year":"2014","journal-title":"JAMA Pediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.47454","article-title":"Prevalence of polycystic ovary syndrome in patients with pediatric type 2 diabetes: a systematic review and meta-analysis","volume":"5","author":"Cioana","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00047-X","article-title":"Obesity in children and adolescents: epidemiology, causes, assessment, and management","volume":"10","author":"Jebeile","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0735","article-title":"Medicaid Expansion and utilization of antihyperglycemic therapies","volume":"43","author":"Sumarsono","year":"2020","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1089\/chi.2021.0090","article-title":"Kids n fitness junior: outcomes of an evidence-based adapted weight management program for children ages three-seven years","volume":"18","author":"Lipton-Inga","year":"2022","journal-title":"Child Obes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.337","article-title":"Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study","volume":"20","author":"Kelly","year":"2012","journal-title":"Obesity"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046956","article-title":"Prevalence of and risk factors for diabetes mellitus in the school-attending adolescent population of the united Arab Emirates: a large cross-sectional study","volume":"11","author":"Barakat","year":"2021","journal-title":"BMJ Open"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in children and adolescents with type 2 diabetes","volume":"381","author":"Tamborlane","year":"2019","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2275","article-title":"Once-weekly exenatide in youth with type 2 diabetes","volume":"45","author":"Tamborlane","year":"2022","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02247-9","article-title":"A century past the discovery of insulin: global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries","volume":"398","author":"Bhutta","year":"2021","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/pedi.13409","article-title":"ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents","volume":"23","author":"Shah","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jpeds.2006.08.042","article-title":"Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the bogalusa heart study","volume":"150","author":"Freedman","year":"2007","journal-title":"J Pediatr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/1574886315999201208212356","article-title":"Efficacy and cardiovascular safety of GLP-1 receptor analogues","volume":"16","author":"Iqbal","year":"2021","journal-title":"Curr Drug Saf"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2018.11.008","article-title":"GLP-1 receptor agonists and cardiovascular outcome trials: an update","volume":"60","author":"Andrikou","year":"2019","journal-title":"Hellenic J Cardiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03699.x","article-title":"Exenatide plus metformin compared with metformin alone on \u03b2-cell function in patients with type 2 diabetes","volume":"29","author":"Derosa","year":"2012","journal-title":"Diabetes Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.01.013","article-title":"Gender-related different effects of a combined therapy of exenatide and metformin on overweight or obesity patients with type 2 diabetes mellitus","volume":"30","author":"Quan","year":"2016","journal-title":"J Diabetes Complications"},{"key":"B29","doi-asserted-by":"publisher","first-page":"107548","DOI":"10.1016\/j.jdiacomp.2020.107548","article-title":"Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight\/obese women with recent gestational diabetes: a double-blind, randomized, placebo-controlled study","volume":"34","author":"Elkind-Hirsch","year":"2020","journal-title":"J Diabetes Complications"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30267-4","article-title":"Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.23.2873","article-title":"Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial","volume":"293","author":"Chanoine","year":"2005","journal-title":"Jama"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1077","article-title":"Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients","volume":"27","author":"Damci","year":"2004","journal-title":"Diabetes Care"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190882","article-title":"Potential drug-drug interactions and their risk factors in pediatric patients admitted to the emergency department of a tertiary care hospital in Mexico","volume":"13","author":"Morales-R\u00edos","year":"2018","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnur.2018.04.008","article-title":"Polycystic ovary syndrome","volume":"53","author":"Meier","year":"2018","journal-title":"Nurs Clin North Am"},{"key":"B36","doi-asserted-by":"publisher","first-page":"101272","DOI":"10.1016\/j.beem.2019.04.006","article-title":"Polycystic ovary syndrome in adolescents","volume":"33","author":"Dabadghao","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch","year":"2022","journal-title":"Fertil Steril"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa692","article-title":"Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-label, parallel-group controlled study","volume":"106","author":"Tao","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Elkind-Hirsch","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01666-6","article-title":"The effectiveness and safety of liraglutide in treating overweight\/obese patients with polycystic ovary syndrome: a meta-analysis","volume":"45","author":"Ge","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"B43","article-title":"Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with hashimoto's thyroiditis","volume":"20","author":"Jin","year":"2015","journal-title":"J Res Med Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.927859","article-title":"Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials","volume":"13","author":"Hu","year":"2022","journal-title":"Front Endocrinol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2337\/figshare.21357237","article-title":"GLP-1 receptor agonists and the risk of thyroid cancer","volume":"46","author":"Bezin","year":"2022","journal-title":"Diabetes Care"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(21)00374-6","article-title":"Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis","volume":"6","author":"Noubiap","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020786","article-title":"Metabolic syndrome: updates on pathophysiology and management in 2021","volume":"23","author":"Fahed","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ecl.2013.09.009","article-title":"Metabolic syndrome","volume":"43","author":"Samson","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.clindermatol.2017.09.004","article-title":"Pathophysiology of the metabolic syndrome","volume":"36","author":"McCracken","year":"2018","journal-title":"Clin Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17512433.2018.1429910","article-title":"The pharmacological management of metabolic syndrome","volume":"11","author":"Rask Larsen","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S137527","article-title":"Current treatment options for acanthosis nigricans","volume":"11","author":"Patel","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ12-0074","article-title":"The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with prader-willi syndrome","volume":"59","author":"Senda","year":"2012","journal-title":"Endocr J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12131","article-title":"Effects of exenatide on weight and appetite in overweight adolescents and young adults with prader-willi syndrome","volume":"12","author":"Salehi","year":"2017","journal-title":"Pediatr Obes"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14583","article-title":"The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in prader-willi syndrome: a systematic review","volume":"96","author":"Ng","year":"2022","journal-title":"Clin Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1170127\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T04:25:02Z","timestamp":1686630302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1170127\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":54,"alternative-id":["10.3389\/fendo.2023.1170127"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1170127","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"article-number":"1170127"}}